Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft

Equities researchers at Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a report released on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $67.00 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price points to a potential upside of 70.70% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Stock Up 0.1 %

Xenon Pharmaceuticals stock opened at $39.25 on Tuesday. Xenon Pharmaceuticals has a 52 week low of $35.53 and a 52 week high of $50.99. The company’s 50 day moving average price is $39.97 and its two-hundred day moving average price is $40.64. The stock has a market cap of $2.99 billion, a P/E ratio of -13.92 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the firm posted ($0.73) EPS. On average, equities analysts anticipate that Xenon Pharmaceuticals will post -3.13 EPS for the current year.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 16,315 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,267,731. This trade represents a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gary Patou sold 4,891 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now owns 23,573 shares in the company, valued at $968,378.84. This trade represents a 17.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,383 shares of company stock valued at $2,535,891. 5.52% of the stock is currently owned by company insiders.

Institutional Trading of Xenon Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Swiss National Bank boosted its position in shares of Xenon Pharmaceuticals by 1.0% during the 4th quarter. Swiss National Bank now owns 126,600 shares of the biopharmaceutical company’s stock valued at $4,963,000 after acquiring an additional 1,300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Xenon Pharmaceuticals by 17.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,274 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 2,866 shares during the last quarter. Candriam S.C.A. lifted its position in Xenon Pharmaceuticals by 6.1% in the 4th quarter. Candriam S.C.A. now owns 492,181 shares of the biopharmaceutical company’s stock worth $19,293,000 after buying an additional 28,320 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Xenon Pharmaceuticals in the 4th quarter worth approximately $797,000. Finally, Assetmark Inc. lifted its position in Xenon Pharmaceuticals by 9.7% in the 4th quarter. Assetmark Inc. now owns 21,585 shares of the biopharmaceutical company’s stock worth $846,000 after buying an additional 1,915 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.